Accolate


Also found in: Dictionary, Wikipedia.
Related to Accolate: Accutane, zafirlukast, Singulair

zafirlukast

Accolate

Pharmacologic class: Leukotriene receptor antagonist

Therapeutic class: Antiasthmatic, bronchodilator

Pregnancy risk category B

Action

Antagonizes activity of three leukotrienes at specific receptor sites in airway smooth muscle, inhibiting inflammation

Availability

Tablets (coated): 10 mg, 20 mg

Indications and dosages

Prophylaxis and long-term treatment of asthma

Adults and children ages 12 and older: 20 mg P.O. b.i.d.

Children ages 5 to 11: 10 mg P.O. b.i.d.

Off-label uses

• Exercise-induced bronchospasm
• Chronic urticaria

Contraindications

• Hypersensitivity to drug or its components
• Hepatic impairment, including hepatic cirrhosis

Precautions

Use cautiously in:
• acute asthma attacks
• concurrent use of warfarin
• patients older than age 55
• pregnant patients
• breastfeeding patients (use not recommended)
• children younger than age 5 (safety not established).

Administration

• Give at least 1 hour before or 2 hours after a meal.

Adverse reactions

CNS: headache, dizziness, asthenia, insomnia, depression (especially in children and adolescents)

GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia

Hepatic: hepatic dysfunction including liver failure and death (rare)

Musculoskeletal: joint or back pain, myalgia

Other: fever, infection, pain

Interactions

Drug-drug.Aspirin: increased zafirlukast blood level

Erythromycin, theophylline: decreased zafirlukast blood level

Warfarin: increased warfarin effects, greater risk of bleeding

Drug-food.Any food: decreased rate and extent of zafirlukast absorption

Patient monitoring

• Assess patient's respiratory status to help evaluate drug efficacy.

Monitor liver function tests closely; watch for signs and symptoms of liver dysfunction.

Patient teaching

• Tell patient to take at least 1 hour before or 2 hours after a meal.
• Advise patient to take exactly as prescribed, even if he is symptom-free.

Tell patient to immediately report asthma attack. Advise him not to use drug for rapid relief of bronchospasm.
• Instruct patient to continue taking other asthma drugs unless prescriber directs otherwise.

Instruct patient to immediately report signs and symptoms of liver dysfunction (nausea, anorexia, fatigue, lethargy, pruritus, jaundice, flulike symptoms, or right upper quadrant abdominal pain).
• Instruct patient or caregiver to report insomnia or depression.
• Instruct female patient to consult prescriber if she plans to breastfeed.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and foods mentioned above.

Accolate

(ăk′ə-lāt′)
A trademark for the drug zafirlukast.

Accolate®

Zafirkulast, see there.

Zafirlukast (Accolate)

An inhibitor that prevents leukotrienes from binding to cell receptors; taken over time, zafirlukast can help reduce or prevent asthma symptoms.
References in periodicals archive ?
4 per cent to 2640p as it warned doctors in Canada about potential liver problems associated with its asthma drug Accolate.
In November, 1996, Accolate became the first product in the newest class of asthma drugs (leukotriene modifiers) approved by the Food and Drug Administration.
Accolate and Singulair are taken in tablet form and help prevent inflammation of the lining of the airways in the lungs - the underlying cause of asthma.
With more than 1,300 nominated products and solutions from 330 global companies, the SC Magazine Awards belong to the internationally most acknowledged and renowned accolate in IT security.
Zafirlukast, marketed under the trade name Accolate by AstraZeneca, was approved in September 1996 for the treatment of chronic asthma in patients 12 years of age and older.
Its newest drugs, such as asthma treatment Accolate and migraine tablet Zomig, have both done well.
Unlike most current asthma drugs, which have to be inhaled into the lungs, Accolate is a twice- daily tablet which works by blocking the action of chemicals responsible for the changes in the lung that cause wheezing.
Among the star performers were asthma treatment Accolate, which notched up pounds 45million of sales in the US and is soon to be available in the UK, and cancer treatments Zoladex and Casodex which achieved sales rises of 12 per cent and 43 per cent resp ectively.
Zafirlukast, marketed under the trade name Accolate by AstraZeneca, was approved in September 1996 for treatment of chronic asthma in patients 12 years of age and older.
Drugs giant Zeneca Pharmaceuticals says its anti-asthma pill Accolate is the first new treatment of its kind in the UK and the first alternative to inhaled steroids for 20 years.
Glass was with ICI Pharmaceuticals (subsequently Zeneca) in Wilmington, Delaware where he was responsible for developing the Pulmonary Therapeutics group and for the successful completion of the Phase I, II and III studies of ACCOLATE.
The company said its new Accolate anti-asthma tablet was the first new treatment of its kind in the UK and the first alternative to inhaled steroids for 20 years.